Mitsukuni Murasaki

1.1k total citations
60 papers, 707 citations indexed

About

Mitsukuni Murasaki is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Pharmacology. According to data from OpenAlex, Mitsukuni Murasaki has authored 60 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Psychiatry and Mental health, 11 papers in Cognitive Neuroscience and 9 papers in Pharmacology. Recurrent topics in Mitsukuni Murasaki's work include Schizophrenia research and treatment (17 papers), Epilepsy research and treatment (12 papers) and Sleep and related disorders (8 papers). Mitsukuni Murasaki is often cited by papers focused on Schizophrenia research and treatment (17 papers), Epilepsy research and treatment (12 papers) and Sleep and related disorders (8 papers). Mitsukuni Murasaki collaborates with scholars based in Japan, United States and Netherlands. Mitsukuni Murasaki's co-authors include Jun Ishigooka, Sadanori Miura, Shigenobu Kanba, Masahiro Takeuchi, Philip D. Harvey, Hiroshi Nakamura, Masataka Suzuki, Shigeto Matsushita, Takeshi Sakurai and Masako Okawa and has published in prestigious journals such as Biological Psychiatry, Psychopharmacology and European Journal of Pharmacology.

In The Last Decade

Mitsukuni Murasaki

57 papers receiving 654 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mitsukuni Murasaki Japan 14 274 185 183 175 86 60 707
Jolanta Rabe‐Jabłońska Poland 17 332 1.2× 139 0.8× 61 0.3× 67 0.4× 62 0.7× 98 987
Itiro Shirakawa Brazil 12 236 0.9× 234 1.3× 92 0.5× 205 1.2× 47 0.5× 24 1.2k
Antoni Florkowski Poland 15 110 0.4× 67 0.4× 69 0.4× 61 0.3× 90 1.0× 84 848
P Kielholz Switzerland 15 174 0.6× 88 0.5× 148 0.8× 85 0.5× 177 2.1× 92 803
Nora Chiang United States 16 210 0.8× 139 0.8× 86 0.5× 119 0.7× 24 0.3× 21 1.1k
Murray Rosenthal United States 15 230 0.8× 101 0.5× 352 1.9× 226 1.3× 110 1.3× 23 899
André Tapp United States 13 532 1.9× 153 0.8× 86 0.5× 66 0.4× 69 0.8× 29 887
Marilde Cavuto Italy 12 195 0.7× 180 1.0× 91 0.5× 59 0.3× 63 0.7× 19 689
Charles S. Wilcox United States 16 275 1.0× 171 0.9× 272 1.5× 135 0.8× 35 0.4× 27 806
Marie‐France Poirier France 17 412 1.5× 221 1.2× 112 0.6× 200 1.1× 36 0.4× 34 964

Countries citing papers authored by Mitsukuni Murasaki

Since Specialization
Citations

This map shows the geographic impact of Mitsukuni Murasaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitsukuni Murasaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitsukuni Murasaki more than expected).

Fields of papers citing papers by Mitsukuni Murasaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitsukuni Murasaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitsukuni Murasaki. The network helps show where Mitsukuni Murasaki may publish in the future.

Co-authorship network of co-authors of Mitsukuni Murasaki

This figure shows the co-authorship network connecting the top 25 collaborators of Mitsukuni Murasaki. A scholar is included among the top collaborators of Mitsukuni Murasaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitsukuni Murasaki. Mitsukuni Murasaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yagi, Kazuichi, Shigeki Kameyama, Sunao Kaneko, et al.. (2012). A Multicenter Open-Labeled, Follow-up Trial of Levetiracetam in Japanese Epilepsy Patients with Partial Onset Seizures. Journal of the Japan Epilepsy Society. 29(3). 441–454. 1 indexed citations
2.
Kohsaka, Masako, Takashi Kanemura, Mitsutaka Taniguchi, et al.. (2011). Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia. Expert Review of Neurotherapeutics. 11(10). 1389–1397. 24 indexed citations
3.
Yagi, Kazuichi, Shigeki Kameyama, Sunao Kaneko, Mitsukuni Murasaki, & Toshio Yamauchi. (2010). Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Levetiracetam as Add-On Therapy in Japanese Patients with Uncontrolled Partial Seizures. Journal of the Japan Epilepsy Society. 28(1). 3–16. 8 indexed citations
4.
Murasaki, Mitsukuni. (2003). Congratulatory message from the President of the Japanese Society of Sleep Research: Launching of Sleep and Biological Rhythms. Sleep and Biological Rhythms. 1(1). 1–1. 2 indexed citations
5.
Higuchi, Sei, Mitsukuni Murasaki, Shigeto Matsushita, et al.. (2002). Plasma orexin-A is lower in patients with narcolepsy. Neuroscience Letters. 318(2). 61–64. 64 indexed citations
6.
7.
Suzuki, Masakazu, et al.. (2000). The effect of zolpidem and zopiclone on memory.. PubMed. 20(2). 61–9. 13 indexed citations
8.
Murasaki, Mitsukuni, et al.. (2000). Olanzapine optimal dose: Results of an open‐label multicenter study in schizophrenic patients. Psychiatry and Clinical Neurosciences. 54(4). 467–478. 14 indexed citations
9.
Ishigooka, Jun, et al.. (1999). Epidemiological study on sleep habits and insomnia of new outpatients visiting general hospitals in Japan. Psychiatry and Clinical Neurosciences. 53(4). 515–522. 37 indexed citations
10.
Murasaki, Mitsukuni, et al.. (1998). Phase I Clinical Study of MCI-186(Edaravone, 3-methyl-1-phenyl-2-pyrazolin-5-one) in Healthy Volunteers: Safety and Pharmacokinetics of Single and Multiple Administrations.. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 29(6). 863–876. 33 indexed citations
11.
Yokota, Shin‐ichi, et al.. (1997). A Pharmacokinetic Study of MCI-186, a Novel Drug for Cerebrovascular Disease in Elderly and Young Health Subjects.. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 28(3). 693–702. 17 indexed citations
12.
Ishigooka, Jun, et al.. (1996). Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant.. PubMed. 16(1). 25–31. 6 indexed citations
13.
Mori, Atsuyoshi, et al.. (1993). Clinical Evaluation of Passiflamin (Passiflora Extract) on Neurosis. Multi-center, double-blind study in comparison with Mexazolam.. 21(3). 383–440. 5 indexed citations
14.
Takahashi, Akihisa, et al.. (1990). Adversive seizure status: Case reports. Electroencephalography and Clinical Neurophysiology. 75. S148–S148.
15.
Murasaki, Mitsukuni, et al.. (1989). Comparison of therapeutic efficacy of neuroses between CM6912 (ethyl loflazepate) and diazepam in a double-blind trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 13(1-2). 145–154. 3 indexed citations
16.
Murasaki, Mitsukuni, et al.. (1989). Phase I study of a new antianxiety drug, buspirone. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 13(1-2). 137–144. 12 indexed citations
17.
Murasaki, Mitsukuni & Akihiko Takahashi. (1988). Complex Partial Status Epilepticus. Psychiatry and Clinical Neurosciences. 42(3). 515–519. 2 indexed citations
18.
Murasaki, Mitsukuni, et al.. (1983). Psychomotor Status–A Female Case in the 34th Week of Pregnancy. Psychiatry and Clinical Neurosciences. 37(4). 435–442. 3 indexed citations
19.
Kariya, Tetsuhiko, Y Shimazono, Ito H, et al.. (1983). A Comparison of the Clinical Effects of Timiperone, a New Butyrophenone Derivative, and Haloperidol on Schizophrenia Using a Double-Blind Technique. Journal of International Medical Research. 11(2). 66–77. 5 indexed citations
20.
Murasaki, Mitsukuni, et al.. (1980). Psychomotor Status: Case Reports and Proposal for Classification. Psychiatry and Clinical Neurosciences. 34(3). 397–397. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jolanta Rabe‐Jabłońska Breakdown of academic impact, for papers by Itiro Shirakawa Breakdown of academic impact, for papers by Antoni Florkowski Breakdown of academic impact, for papers by P Kielholz Breakdown of academic impact, for papers by Nora Chiang Breakdown of academic impact, for papers by Murray Rosenthal Breakdown of academic impact, for papers by André Tapp Breakdown of academic impact, for papers by Marilde Cavuto Breakdown of academic impact, for papers by Charles S. Wilcox Breakdown of academic impact, for papers by Marie‐France Poirier
Rankless by CCL
2026